(Q43906723)

27 November 2017

High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis (English)

1 reference

27 November 2017

1 reference

1 reference

B Tanriover

1

1 reference

27 November 2017

S E Wright

2

1 reference

27 November 2017

S V Foster

3

1 reference

27 November 2017

K S Roush

4

1 reference

27 November 2017

J A Castillo-Lugo

5

1 reference

27 November 2017

K Fa

6

1 reference

27 November 2017

F L Levy

7

1 reference

27 November 2017

A Mejia

8

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

Transplantation Proceedings

27 November 2017

1 reference

27 November 2017

40

1 reference

27 November 2017

10

1 reference

27 November 2017

3393-3396

1 reference

Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Banff 2003 meeting report: new diagnostic insights and standards.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Rituximab therapy for acute humoral rejection after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

National conference to assess antibody-mediated rejection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

IVIG rescue therapy in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Rituximab as treatment for refractory kidney transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

Determinants of poor graft outcome in patients with antibody-mediated acute rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2008.08.131

10.1016/J.TRANSPROCEED.2008.08.131

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference